Indication
ERBB2-mutated Tumors
2 clinical trials
4 products
1 drug
Clinical trial
Disitamab Vedotin（RC48）Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 AlterationsStatus: Not yet recruiting, Estimated PCD: 2025-07-01
Product
Disitamab VedotinDrug
pyrotinibClinical trial
Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC With HER2 Alterations, a Phase II StudyStatus: Not yet recruiting, Estimated PCD: 2024-10-01
Product
RC48+Furmonertinib